Evaluation of the effect of Escitalopram versus placebo trial on changing the neuroticism

Phase 2

• Conditions: euroticism or neuroticism.; Post-traumatic stress disorder, acute; F43.11

• Registration Number: IRCT20211208053331N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 172

Inclusion Criteria

Neuroticism traits based on NEO-60 questionnaire with a score higher than 24
?Age-range 24-45 years old
Obtaining informed consent from the individuals

Exclusion Criteria

Pregnancy or intention to conceive
Lactation
Presence of psychiatric disorder based on GHQ questionnaire with a score above 23
Previous history of SSRI antidepressant intolerance
Patients with severe side effects of citalopram
Patients with a history of chronic diseases such as brain and heart disease, vascular, seizures
People with a history of drug abuse.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Flexibility. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.;Responsibility. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.;Psychotic. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.;Extraversion. Timepoint: At the beginning of the study, 2 and 4 weeks after intervention. Method of measurement: Personality Inventory-Revised questionnaire.